Carregant...
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Historically, research and development (R&D) in the pharmaceutical sector has predominantly been an in-house activity. To enable investments for game changing late-stage assets and to enable better and less costly go/no-go decisions, most companies have employed a fail early paradigm through the...
Guardat en:
| Publicat a: | J Transl Med |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5941640/ https://ncbi.nlm.nih.gov/pubmed/29739427 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-018-1499-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|